Story perspectives
Alzheimer's Treatments Show Promise Amidst Concerns and Challenges
9/22/2025
50 4
1 of 1
Story summary
- Donanemab and lecanemab provide modest hope for Alzheimer's patients, but concerns about their effectiveness and side effects persist.
- Lecanemab is U.S.-approved but faces cost-benefit reimbursement issues in France and the UK.
- A new U.S. blood test for Alzheimer's biomarkers lacks European approval.
- European specialists stress the importance of comprehensive clinical exams for accurate diagnosis.
- Nearly half of Alzheimer's cases relate to lifestyle factors, yet trials on lifestyle changes show limited success.
